DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.428,506 B2 Mates Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.428,506 B2 Mates Et Al USOO9428506B2 (12) United States Patent (10) Patent No.: US 9.428,506 B2 Mates et al. (45) Date of Patent: Aug. 30, 2016 (54) SUBSTITUTED (56) References Cited PYRIDO3',4':45PYRROLO1,2,3-DE) QUINOXALINES FOR THE TREATMENT OF U.S. PATENT DOCUMENTS NERVOUS SYSTEM DSORDERS 4,001,263. A 1, 1977 Plattner 4.389,330 A 6, 1983 Tice et al. (71) Applicant: INTRA-CELLULAR THERAPIES, 4,530,840 A 7, 1985 Tice INC., New York, NY (US) 5,538,739 A 7/1996 Bodmer 6,548.493 B1 4/2003 Robichaud 6,552,017 B1 4/2003 Robichaud (72) Inventors: Sharon Mates, New York, NY (US); 6,713,471 B1 3/2004 Robichaud Robert Davis, New York, NY (US); 7,081.455 B2 7/2006 Robichaud Peng Li, New York, NY (US); 7,183,282 B2 2/2007 Robichaud Lawrence Wennogle, New York, NY RE39,679 E 6/2007 Robichaud (US); Kimberly Vanover, New York, RE39,680 E 6/2007 Robichaud 7,238,690 B2 7/2007 Robichaud NY (US) 8,309,722 B2 11/2012 Tomesch (73) Assignee: INTRA-CELLULAR THERAPIES, (Continued) INC., New York, NY (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 EP 00584.81 8, 1982 U.S.C. 154(b) by 0 days. EP 0976732 A1 2, 2000 (Continued) (21) Appl. No.: 14/394,467 OTHER PUBLICATIONS U.S. Appl. No. 14/627,968, filed Feb. 20, 2015, Mates. (22) PCT Fed: Apr. 14, 2013 International Preliminary Report on Patentability for International Application No. PCT/US2013/036514 issued Oct. 14, 2014. (86) PCT No.: PCT/US2O13/036514 Written Opinion of the International Searching Authority for Inter national Application No. PCT/US2013/036514 mailed Aug. 16, S 371 (c)(1), 2013. (2) Date: Oct. 14, 2014 U.S. Appl. No. 61/975,502, filed Apr. 4, 2014, Mates et al. U.S. Appl. No. 61/975,610, filed Apr. 4, 2014, Mates et al. (87) PCT Pub. No.: WO2O13A1SSSOS U.S. Appl. No. 62/009,849, filed Jun. 9, 2014, Davis et al. U.S. Appl. No. 62/015, 120, filed Jun. 20, 2014, Mates et al. PCT Pub. Date: Oct. 17, 2013 Bryan-Lluka, L. J. et al., “Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin (65) Prior Publication Data transporters in transfected COS-7 cells', Naunyn-Shemiedeberg's US 2015/OO79172 A1 Mar. 19, 2015 Arch Pharmacol, 1999, vol. 360, pp. 109-115. (Continued) Related U.S. Application Data Primary Examiner — Douglas M. Willis (60) Provisional application No. 61/671,713, filed on Jul. (74) Attorney, Agent, or Firm — Hoxie & Associates LLC 14, 2012, provisional application No. 61/624.293, (57) ABSTRACT filed on Apr. 14, 2012, provisional application No. The invention relates to particular substituted heterocycle 61/624.291, filed on Apr. 14, 2012, provisional fused gamma-carbolines, of Formula I, in free, Solid, phar application No. 61/624.292, filed on Apr. 14, 2012, maceutically acceptable salt and/or Substantially pure form provisional application No. 61/671,723, filed on Jul. as described herein, pharmaceutical compositions thereof, 14, 2012. and methods of use in the treatment of diseases involving 5-HT, receptor, serotonin transporter (SERT) and/or path (51) Int. C. ways involving dopamine D receptor signaling systems. A6 IK 3/4985 (2006.01) Such as disease of the central nervous system. CO7D 24I/38 (2006.01) CO7D 47L/4 (2006.01) A6 IK 45/06 (2006.01) Formula I A6 IK3I/5383 (2006.01) CO7D 47L/6 (2006.01) F A6 IK 3/445 (2006.01) (52) U.S. C. CPC ........... C07D 471/14 (2013.01); A61K 31/445 (2013.01); A61 K3I/4985 (2013.01); A61 K R2 RI 3 1/5383 (2013.01); A61K 45/06 (2013.01); C07D 471/16 (2013.01) H (58) Field of Classification Search X CPC ......................... A61K 31/4985; C07D 241/38 USPC ........................................... 514/250; 544/343 See application file for complete search history. 30 Claims, No Drawings US 9,428,506 B2 Page 2 (56) References Cited WO WO 2009, 145900 12/2009 WO WO 2011, 133224 10, 2011 U.S. PATENT DOCUMENTS WO WO 2013,155504 10, 2013 WO WO 2013,155.505 10, 2013 8,598,119 B2 12/2013 Mates WO WO 2013,155506 10, 2013 8,648,077 B2 2, 2014 Tomesch WO WO 2014f145.192 9, 2014 8,779,139 B2 T/2014 Tomesch WO WO 2015,085.004 6, 2015 8,993,572 B2 3/2015 Mates 2004/0092534 A1 5, 2004 Yam et al. OTHER PUBLICATIONS 2004/O142970 A1 T/2004 Chung Foster, "Acetylcholinesterase inhibitors reduce spreading activation 2004/0180875 A1 9, 2004 Lee et al. in dementia,” Neuropsychologia, 2012, 50, 2093-2099. 2004/022O178 A1 11, 2004 Robichaud et al. Hackman, JAMA 2006, 296(14), 1731-1732. 2008, OO69885 A1 3, 2008 Mesens et al. Harbert, C.A. et al., “Neuroleptic Activity in 5-Aryltetrahydro-y- 2008/O132552 A1 6, 2008 Kleinman carbolines”. J. Med. Chem., 1980, vol. 23, pp. 635-643. 2008/0280941 A1 11, 2008 Lourtie Harvey, "Serotonin and Stress: Protective or Malevolent Actions in 2009/0202631 A1 8, 2009 Yam the Biobehavioral Response to Repeated Trauma?' Annals of the 2010, O298382 A1 11, 2010 Seeman New York Academy of Sciences, 1032: 267-272 (2004) doi: 2011 0071080 A1 3, 2011 Mates 10.1196, annals. 1314.035. 2011/0112105 A1 5, 2011 Tomesch Jordan, V.C. Nature Reviews. Drug Discovery, 2003, 2:205. 2014/0050783 A1 2, 2014 Mates Khorana, et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin 2014/0323491 A1 10, 2014 Tomesch Receptors'. Bioorganic & Medicinal Chemistry, (2003), vol. 11, 2014/0364609 A1 12, 2014 Tomesch Issue 5, 6, pp. 717-722, p. 718 Table 1. 2015.OO72964 A1 3/2015 Mates et al. Lebert, “Trazodone in Fronto-Temporal Dementia'. Research and 2015.OO79172 A1 3/2015 Mates et al. Practice in Alzheimer's Disease, 2006, vol. 11, 356-360. 2015, 0080404 A1 3/2015 Mates et al. Lee, “Novel, highly potent, selective 5-HT2A/D2 receptor antago nists as potential atypical antipsychotics.” Bioorganic & Medicinal FOREIGN PATENT DOCUMENTS Chemistry Letters, 2003, vol. 13, Issue 4, pp. 767-770. Lounkine, “Formal Concept Analysis for the Identification of EP 1539115 6, 2005 Molecular Fragment Combinations Specific for Active and Highly GB 1476087 6, 1977 Potent Compounds,” J. Med. Chem., 2008, 51 (17), 5342-5348. GB 2145422 3, 1985 WO WO 94,241.25 10, 1994 March, Advanced Organic Chemistry, Reactions, Mechanisms and WO WO95/13814 5, 1995 Structures, Fourth Edition, pp. 910-911 (1992). WO WO 98.43956 10, 1998 Pond, S.M. et al. “Stereospecific reduction of haloperidol in human WO WOOO,35419 6, 2000 tissues'. Biochemical Pharmacology, vol. 44 (5), p. 867-871 WO WOOO,770O2 A1 12, 2000 (1992). WO WOOOf 77010 12/2000 Weschules, "Acetylcholinesterase Inhibitor and N-Methyl-D- WO WO 2004/O10981 2, 2004 Aspartic Acid Receptor Antagonist Use among Hospice Enrollees WO WO 2008, 112280 9, 2008 with a Primary Diagnosis of Dementia'. Journal of Palliative WO WO 2009/114181 9, 2009 Medicine, 2008, vol. 11, No. 5, 738-745. US 9,428,506 B2 1. 2 SUBSTITUTED out affecting or minimally affecting dopamine D receptors, PYRIDO3',4':45PYRROLO1,2,3-DE) thereby useful for the treatment of sleep disorders without QUINOXALINES FOR THE TREATMENT OF the side effects of the dopamine D pathways or side effects of other pathways (e.g., GABA receptors) associated with NERVOUS SYSTEM DSORDERS convention sedative-hypnotic agents (e.g., benzodiazepines) including but not limited to the development of drug depen CROSS REFERENCE TO RELATED dency, muscle hypotonia, weakness, headache, blurred APPLICATIONS vision, Vertigo, nausea, vomiting, epigastric distress, diar rhea, joint pains, and chest pains. This application is a national phase application filed under WO 2009/114181 discloses methods of preparing tolu 35 U.S.C. S371 of International Application No. PCT/ 10 enesulfonic acid addition salt crystals of particular Substi US2013/036514, filed on Apr. 14, 2013, which International tuted heterocycle fused gamma-carbolines, e.g., toluenesul Application claims priority from U.S. Provisional Applica fonic acid addition salt of 4-((6bR.10aS)-3-methyl-2,3,6b, tion Nos. 61/624,293, 61/624,292 and 61/624,291, all filed 9,10,10a-hexahydro-1H-pyrido3',4':45pyrrolo 1,2,3-de on Apr. 14, 2012; and U.S. Provisional Application Nos. quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone. 61/671,723 and 61/671,713, both filed on Jul 14, 2012, the 15 WO 2011/133224 discloses prodrugs/metabolites of sub contents of each of which are incorporated by reference in stituted heterocycle fused gamma-carboline for improved their entirety. formulation, e.g., extended/controlled release formulation. This application discloses that heterocycle fused gamma FIELD OF THE INVENTION carboline N-substituted with a 4-fluorophenyl(4-hydroxy) butanyl moiety are shown to have high selectivity for the The invention relates to particular substituted heterocycle serotonin transporter (SERT) relative to the heterocycle fused gamma-carbolines, in free, pharmaceutically accept fused gamma-carboline containing 4-fluorophenylbutanone. able salt and/or substantially pure form as described herein, The hydroxy group on these compounds, however, is inter pharmaceutical compositions thereof, and methods of use in converted to and from the ketone within the plasma and the the treatment of diseases involving 5-HT, receptor, sero 25 brain, allowing it to serve as a reservoir for the 4-fluoro tonin transporter (SERT) and/or pathways involving dop phenylbutanone drug. For the first time, the current invention provides com amine D receptor signaling systems, e.g., diseases or dis pounds which block the in vivo inter-conversion between orders such as anxiety, psychosis, Schizophrenia, sleep the hydroxy and the ketone, yielding compounds which disorders, sexual disorders, migraine, conditions associated antagonize 5-HT2A receptors and also inhibit serotonin with cephalic pain, social phobias, gastrointestinal disorders 30 re-uptake transporter.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • A Phase 3, Multicenter, Randomized, Double-Blind
    Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment NCT Number: NCT03999918 Document Date: 21 Jun 2020 CLINICAL STUDY PROTOCOL UNMASKED PROTOCOL A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment Protocol Number: ACP-103-054 Amendment 4 EudraCT Number: 2018-003251-37 Original Protocol Date: 30 August 2018 Protocol Amendment 1 Date: 05 December 2018 Protocol Amendment 2 Date: 18 March 2019 Protocol Amendment 3 Date: 29 October 2019 Protocol Amendment 4 Date: 21 June 2020 Confidentiality Statement This protocol is the confidential information of ACADIA Pharmaceuticals Inc. and is intended solely for the guidance of the clinical investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the prior written consent of ACADIA Pharmaceuticals Inc. Confidential and Proprietary Information of ACADIA Pharmaceuticals Inc. Page 1 of 81 Study: ACP-103-054 Final Version: 1.0 Clinical Study Protocol Amendment 4 UNMASKED VERSION Date: 21 June 2020 SPONSOR SIGNATURE PAGE Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment ACADIA President: President ACADIA Pharmaceuticals Inc. See appended electronic signature page Signature Date ACADIA Study Lead: Executive Director, Clinical Research ACADIA Pharmaceuticals Inc.
    [Show full text]
  • Emerging Anti-Insomnia Drugs: Tackling Sleeplessness and the Quality of Wake Time
    REVIEWS Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time Keith A. Wafford* and Bjarke Ebert‡ Abstract | Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep–wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep. Primary insomnia Humans spend approximately one-third of their lifetime Insomnia is defined as difficulty in initiating and/or Patients who suffer from sleeping, but we still know relatively little about why this maintaining sleep. The incidence of insomnia in the gen- sleeplessness for at least process is so critical for every living animal. Current eral population is between 10–30%, and approximately 1 month that cannot be thinking suggests that waking activity is relatively 50% of the cases complain of serious daytime conse- attributed to a medical, dynamic in terms of using the body’s resources: breaking quences, such as inability to concentrate, reduced energy psychiatric or an environmental cause (such as drug abuse or down proteins, gathering information and expending and memory problems. When this persists for more medications).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • Copyright by Holly L. Chapman 2020
    Copyright by Holly L. Chapman 2020 EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS by Holly L. Chapman, B.S. THESIS Presented to the Faculty of The University of Houston-Clear Lake In Partial Fulfillment Of the Requirements For the Degree MASTER OF SCIENCE in Psychology THE UNIVERSITY OF HOUSTON-CLEAR LAKE MAY, 2020 EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS by Holly L. Chapman APPROVED BY __________________________________________ Christopher P. Ward, Ph.D., Chair __________________________________________ David H. Malin, Ph.D., Co-Chair RECEIVED/APPROVED BY THE COLLEGE OF HUMAN SCIENCES AND HUMANITIES: Samuel Gladden, Ph.D., Associate Dean __________________________________________ Rick Short, Ph.D., Dean Dedication To my family, whose unflinching support means the world to me and I hope one day I can return in kind. Acknowledgements To everyone else that believed, persisted, and achieved around me and gave me the strength to do the same. Special acknowledgements go out to my thesis committee Dr. Ward and Dr. Malin for having the patience to get this project off the ground, again, and make the most of our resources. Huge thanks to Joseph R. Campbell and Ping Sun Tsai for fast-tracking my motivation/sanity and digging into the science and reviewing my writing with me. v ABSTRACT EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS Holly L. Chapman University of Houston-Clear Lake, 2020 Thesis Chair: Dr. Christopher P. Ward Co-Chair: Dr.
    [Show full text]
  • | Hai Lama at Matalun Alun Alt Palma Hati
    |HAI LAMA AT MATALUNUS009801847B2 ALUN ALT PALMA HATI (12 ) United States Patent (10 ) Patent No. : US 9 ,801 , 847 B2 Dubé et al. (45 ) Date of Patent: * Oct. 31, 2017 ( 54 ) DOXEPIN ISOMERS AND ISOMERIC (60 ) Provisional application No . 60 /898 ,376 , filed on Jan . MIXTURES AND METHODS OF USING THE 30 , 2007 , provisional application No. 60 /801 , 824 , SAME TO TREAT SLEEP DISORDERS filed on May 19 , 2006 , provisional application No. 60 / 833 , 319 , filed on Jul. 25 , 2006 . ( 71) Applicants : Pernix Sleep , Inc ., Morristown , NJ (US ) ; ProCom One, Inc. , San Marcos , (51 ) Int . Cl. TX (US ) A61K 31 /335 (2006 . 01) (52 ) U . S . CI. @(72 ) Inventors : Susan E . Dubé, Carlsbad , CA (US ) ; CPC .. .. .. .. .. .. .. A61K 31/ 335 (2013 .01 ) Neil B . Kavey , Chappaqua , NY (US ) (58 ) Field of Classification Search CPC . .. .. .. .. .. .. .. A61K 31/ 335 @( 73 ) Assignees: Pernix Sleep , Inc. , Morristown , NJ See application file for complete search history . (US ) ; ProCom One, Inc . , San Marcos , TX (US ) (56 ) References Cited ( * ) Notice : Subject to any disclaimer , the term of this U . S . PATENT DOCUMENTS patent is extended or adjusted under 35 6 ,211 ,229 B1 * 4 /2001 Kavey .. .. .. .. A61K 31 /13 U . S . C . 154 (b ) by 0 days . 514 /217 This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Wyatt et. al. , Applied Spectroscopy , 1986 , Society for Applied (21 ) Appl . No. : 15 /289 , 288 Spectroscopy, vol. 40 ( 4 ), pp . 538 -542 . * ( 22 ) Filed : Oct . 10 , 2016 * cited by examiner (65 ) Prior Publication Data Primary Examiner — Sarah Pihonak US 2017 /0020839 A1 Jan . 26 , 2017 (74 ) Attorney , Agent, or Firm — Servilla Whitney LLC Related U .
    [Show full text]
  • ( 12 ) United States Patent
    US009737531B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 737 ,531 B2 Javitt ( 45) Date of Patent : Aug . 22 , 2017 ( 54 ) COMPOSITION AND METHOD FOR 2008 /0194698 A1 * 8 / 2008 Hermanussen et al. .. .. 514 /662 TREATMENT OF DEPRESSION AND 2011/ 0207776 A18 / 2011 Buntinx 2011 /0306586 Al 12 / 2011 Khan PSYCHOSIS IN HUMANS 2012 /0041026 A12 / 2012 Waizumi (71 ) Applicant : Daniel C Javitt , Bardonia , NY (US ) FOREIGN PATENT DOCUMENTS ( 72 ) Inventor: Daniel C Javitt, Bardonia , NY (US ) CN 101090721 12 / 2007 KR 2007 0017136 A 2 / 2007 ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee, NJ (US ) WO WO 2005 /000216 A2 1 / 2005 WO WO 2005 /065308 A2 7 / 2005 ( * ) Notice : Subject to any disclaimer , the term of this WO WO 2005 /079756 9 / 2005 patent is extended or adjusted under 35 WO 2011044089 4 / 2011 U . S . C . 154 ( b ) by 0 days . wo WO 2012 / 104852 Al 8 / 2012 ( 21 ) Appl. No. : 13 /936 , 198 OTHER PUBLICATIONS Ceglia et al. , “ The 5 -HT2A receptor antagonist M100 , 907 prevents ( 22 ) Filed : Jul. 7 , 2013 extracellular glutamate rising in response to NMDA receptor block ade in the mPFC ,” Journal of Neurochemistry , 2004 , 91 , 189 - 199 . * ((65 65 ) Prior Publication Data Mony et al. , “ Identification of a novel NR2B -selective NMDA US 2014 / 0018348 A1 Jan . 16 , 2014 receptor antagonist using a virtual screening approach , ” Bioorganic & Medicinal Chemistry Letters 20 ( 2010 ) 5552 - 5558 . * Ceglia et al ., “ The 5HT2A receptor antagonist M100 , 907 prevents Related U . S . Application Data extracellular glutamate rising in response to NMDA receptor block ( 60 ) Provisional application No .
    [Show full text]
  • Treatment of Chronic Pain by Medical Approaches the AMERICAN ACADEMY of PAIN MEDICINE Textbook on Patient Management Treatment of Chronic Pain by Medical Approaches
    the AMERICAN ACADEMY of PAIN MEDICINE Timothy R. Deer Vitaly Gordin Editor-in-Chief Associate Editor Michael S. Leong Associate Editor-in-Chief Treatment of Chronic Pain by Medical Approaches the AMERICAN ACADEMY of PAIN MEDICINE Textbook on Patient Management Treatment of Chronic Pain by Medical Approaches Timothy R. Deer Editor-in-chief Michael S. Leong Associate Editor-in-chief Vitaly Gordin Associate Editor Treatment of Chronic Pain by Medical Approaches the AMERICAN ACADEMY of PAIN MEDICINE Textbook on Patient Management Editor-in-chief Associate Editor-in-chief Timothy R. Deer, M.D. Michael S. Leong, M.D. President and CEO Clinic Chief The Center for Pain Relief Stanford Pain Medicine Center Clinical Professor of Anesthesiology Redwood City, CA, USA West Virginia University School of Medicine Clinical Associate Professor Charleston , WV, USA Department of Anesthesiology Stanford University School of Medicine Associate Editor Stanford , CA , USA Vitaly Gordin, M.D. Associate Professor Associate Vice Chair of Pain Management Department of Anesthesiology Pennsylvania State University College of Medicine Director Pain Medicine Milton S. Hershey Medical Center Hershey , PA , USA ISBN 978-1-4939-1817-1 ISBN 978-1-4939-1818-8 (eBook) DOI 10.1007/978-1-4939-1818-8 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2014952895 © American Academy of Pain Medicine 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.
    [Show full text]
  • WO 2020/212952 A1 22 October 2020 (22.10.2020)
    (12) INTERNATIONAL APPLICATION PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization iii iiiii min linn ill II Minim mill ill m International Bureau (10) International Publication Number (43) International Publication Date WO 2020/212952 A1 22 October 2020 (22.10.2020) (51) International Patent Classification: 62/946, 159 10 December 2019 (10. 12.2019) U S A61K 31/675 (2006.01) A61P 25/30 (2006.01) (71) Applicant: COMPASS PATHFINDER LIMITED A61K 31/4045 (2006.01) A61P 25/00 (2006.01) [GB/GB]; 3rd Floor, 1 Ashley Road, Altrincham, Cheshire A61P1/00 (2006.01) A61P 25/06 (2006.01) WA14 2DT (GB). A61P 25/16 (2006.01) A61P25/22 (2006.01) (72) Inventors: LONDESBROUGH, Derek John; 37 Linden (21) International Application Number: Grove, Hartlepool, Durham TS26 9QA (GB). BROWN, PCT/IB2020/053688 Christopher; 30 Cherrytree Gardens, Gateshead, Tyne and (22) International Filing Date: Wear NE9 6TY (GB). NORTHEN, Julian Scott; 36 Hep- 17 April 2020 (17.04.2020) scott Terrace, South Shields, Tyne and Wear NE33 4TH (GB). MOORE, Gillian; 22 Matfen Court, Sedgefield, (25) Filing Language: English Durham TS21 2JB (GB). PATIL, Hemant Kashinath; (26) Publication Language: English 137C Kingston Road, Leatherhead, Surrey KT22 7NT (GB). NICHOLS, David E.; 56702 Nash, Chapel Hill, N C (30) Priority Data: 27517 (US). CROAL, Megan; c/o COMPASS Pathways 62/835,449 17 April 2019 (17.04.2019) U S Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire 62/835,450 17 April 2019 (17.04.2019) U S WA14 2DT (GB). ERIKSSON, Hans Ake; c/o COM¬ 62/835,458 17 April 2019 (17.04.2019) U S PASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrin¬ 62/835,460 17 April 2019 (17.04.2019) U S cham Cheshire WA14 2DT (GB).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Pimavanserin Tartrate: a 5-HT2A Inverse Agonist with Potential for Treating Various 1
    Drug Evaluation Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various 1. Introduction neuropsychiatric disorders 2. Schizophrenia † 3. Psychosis in Parkinson’s disease Atheir Abbas & Bryan L Roth † National Institute of Mental Health Psychoactive Drug Screening Program, 4. 5-HT2A antagonists/inverse University of North Carolina, Lineberger Cancer Center, Medicinal Chemistry, Psychiatry, agonists and sleep Pharmacology, Chapel Hill, NC 27516, USA 5. Chemistry 6. Pharmacodynamics Background : Pimavanserin tartrate is the first 5-HT 2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson’s 7. Pharmacokinetics disease and for augmentation of low-dose risperidone treatment in schizo- 8. Clinical effi cacy (see Table 1 phrenia. Pimavanserin is also being evaluated as a possible anti-insomnia for concise summary) drug. Objective : To discuss the potential of pimavanserin to fill multiple 9. Safety and tolerability therapeutic needs. Methods : The problems with currently approved antipsy- 10. Conclusions chotics and sleep agents are explored to highlight how pimavanserin might 11. Expert opinion address some longstanding issues in the treatment of psychosis and insomnia. Results/conclusions : In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L -dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals. Keywords: 5-HT2A , 5-HT2A , antipsychotic , inverse agonist , Parkinson’s Disease , pimavanserin , For personal use only. psychosis , schizophrenia Expert Opin. Pharmacother. (2008) 9(18):3251-3259 1. Introduction Pimavanserin tartrate (ACP-103, Acadia Pharmaceuticals, Sorrento Valley, CA) is a 5-HT2A inverse agonist in clinical trials for the treatment of psychosis in Parkinson’s disease (PD) and as adjunct therapy in the treatment of schizophrenia.
    [Show full text]